Suppr超能文献

原发性睾丸弥漫性大B细胞淋巴瘤的临床和组织学特征:中国单中心经验

Clinical and histological features of primary testicular diffuse large B-cell lymphoma: a single center experience in China.

作者信息

Zhou De, Bao Changqian, Ye Xiujin, Zhu Lixia, Zhu Jingjing, Li Li, Zhu Mingyu, Yang Xiudi, Zheng Yanlong, Huang Xianbo, Xie Mixue, Xie Wanzhuo

机构信息

Department of Hematology, the First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang Province, China.

Program in Clinical Medicine, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.

出版信息

Oncotarget. 2017 Jul 31;8(68):112384-112389. doi: 10.18632/oncotarget.19736. eCollection 2017 Dec 22.

Abstract

Primary testicular lymphoma (PTL) is a rare and aggressive form of extranodal lymphoma. Approximately 80-98% of PTLs are diffuse large B-cell lymphoma (PT-DLBCL). The prognosis of DLBCL patients has improved with the addition of rituximab to systemic chemotherapy, but outcomes of PT-DLBCL remain poor. This may be explained by the high rate of relapse in the central nervous system (CNS) and contralateral testis. We analyzed 1,132 newly diagnosed DLBCL patients (37 with PT-DLBCL) who were treated at our hospital between January 2009 and December 2014. Twenty-five patients finished follow-up. We analyzed clinical characteristics, response to chemotherapy, overall survival, and relapse in the CNS and contralateral testis. All patients underwent orchiectomy. The median age was 60 (range: 43-82) years. Eleven patients had stage III/IV disease. Five patients experienced CNS relapse, and three experienced relapse in the contralateral testis. Median overall survival (OS) was not reached at the time of reporting. The 3-year OS rate was 57%. None of the nine patients who received radiotherapy to the contralateral testis experienced relapse in that location. Intrathecal prophylaxis did not reduce the risk of CNS relapse. All five patients who experienced CNS relapse had the germinal center B-cell-like subtype of DLBCL.

摘要

原发性睾丸淋巴瘤(PTL)是一种罕见的侵袭性结外淋巴瘤。大约80%-98%的PTL为弥漫性大B细胞淋巴瘤(PT-DLBCL)。随着利妥昔单抗加入全身化疗,DLBCL患者的预后有所改善,但PT-DLBCL的治疗结果仍然较差。这可能是由于中枢神经系统(CNS)和对侧睾丸的高复发率所致。我们分析了2009年1月至2014年12月在我院接受治疗的1132例新诊断的DLBCL患者(37例为PT-DLBCL)。25例患者完成随访。我们分析了临床特征、化疗反应、总生存期以及CNS和对侧睾丸的复发情况。所有患者均接受了睾丸切除术。中位年龄为60岁(范围:43-82岁)。11例患者为Ⅲ/Ⅳ期疾病。5例患者发生CNS复发,3例患者发生对侧睾丸复发。报告时中位总生存期(OS)未达到。3年OS率为57%。9例接受对侧睾丸放疗的患者中无一例在该部位复发。鞘内预防性治疗并未降低CNS复发的风险。所有5例发生CNS复发的患者均为DLBCL的生发中心B细胞样亚型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa1a/5762517/43da3abc537f/oncotarget-08-112384-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验